Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered portable MRI could bring epilepsy diagnosis to millions who lack access

NCT ID NCT07717632

Diagnosis Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study explores whether a low-cost, portable MRI machine enhanced with artificial intelligence can detect brain abnormalities in people with epilepsy as accurately as standard high-field MRI. About 30 adults with epilepsy who have already had a high-field MRI will also receive a low-field MRI scan. Researchers will compare the two scans to see how well the AI-enhanced low-field version identifies lesions, which could make epilepsy diagnosis more accessible in low- and middle-income countries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low-field MRI with AI image enhancement
What this could lead to
If successful, this could make brain imaging for epilepsy diagnosis more accessible and affordable in low-resource settings worldwide.
What could go wrong
This is a small early-stage study, and the AI-enhanced low-field MRI may not detect all abnormalities seen on standard MRI. Results may not generalize to all epilepsy types or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

39 people

The number who actually took part.

Started

Sep 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged between \>17 years and \<70 years 2. Diagnosis of epilepsy and attending at UCLH-affiliated outpatient epilepsy clinic 3. Undergone a 1.5T or 3T MRI Brain scan within 12 months of recruitment as part of standard clinical care 4. Can tolerate MRI scanning without sedation. Exclusion Criteria: 1. Cognitive impairment that precludes ability to consent or assent to the study 2. Inability to lie flat 3. Body habitus incompatible with LF-MRI device 4. Presence of MRI contraindications as stipulated by standard MRI operating procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy

Contacts and locations

Locations

  • UCL Queen Square Institute of Neurology

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.